Fig. 5

Increased NMO pathology in spinal cord of CD59^−/− rats following intracisternal injection of AQP4-IgG. a. Intracisternal model showing microneedle injection of AQP4-IgG (or control IgG). b. Neurological scores at day 3 after AQP4-IgG, control IgG, or engineered AQP4-IgG lacking complement effector function (AQP4-IgG^-CDC). Each symbol is data from a separate rat (n = 6), with mean ± S.E.M. shown (**P < 0.01). c. Immunofluorescence of indicated markers in cervical, thoracic and lumbar spinal cord at 3 days after AQP4-IgG injection. d. Loss of AQP4 and GFAP immunofluorescence normalized to whole section area of spinal cord (mean ± S.E.M., 6 rats per genotype, **P < 0.01). e. C5b-9 and Iba-1 immunofluorescence in cervical and thoracic spinal cord at 3 days after AQP4-IgG injection. f. AQP4-IgG distribution at 2 h after intracisternal injection visualized with an anti-human secondary antibody